Bifidobacterium breve | |
---|---|
Scientific classification | |
Domain: | Bacteria |
Phylum: | Actinomycetota |
Class: | Actinomycetia |
Order: | Bifidobacteriales |
Family: | Bifidobacteriaceae |
Genus: | Bifidobacterium |
Species: | B. breve |
Binomial name | |
Bifidobacterium breve Reuter 1963 (Approved Lists 1980) | |
Bifidobacterium breve is a bacterial species of the genus Bifidobacterium which has probiotic properties. [1] [2] Bifidobacteria are a type of bacteria that live symbiotically in the intestines of humans. They have been used to treat a number of conditions including constipation, diarrhea, irritable bowel syndrome and even the cold and flu. Some of these uses have been backed up by scientific research, but others have not. [3] B. breve is a gram positive, anaerobic, rod shaped organism that is non motile and forms branches with its neighbors. [4]
B. breve has been researched and linked to a number of conditions. Bifidobacterium breve administered in combination with prebiotics or other probiotics and standard therapy has shown some beneficial effect. [5] B. breve is a constituent in the therapeutic, nutritional treatment of IBD. This proprietary, standardized, formulation of live bacteria is used to treat ulcerative colitis and may require a prescription. [5] [6] Taking Bifidobacteria in combination with Lactobacillus and normal Helicobacter pylori therapy makes the treatment twice as effective while reducing the negative side effects. Bifidobacteria can also be used to treat IBS as well, reducing pain, bloating and constipation. [3]
B. breve may be linked to chronic obesity. A growing pool of evidence suggests that variations in the human gut microbiome correlate with excess weight gain. B.breve is a strong candidate for research concerning this issue. A study conducted by Bioscience of Microbiota, Food and Heath(BMFH) suggests that treating pre-obese patients with the B-3 strain of B. breve may stop or reverse obesity. [7] However larger studies need to be performed to confirm these results.
Bifidobacteria and its link to stomach health are being researched along with its link to the brain through the microbiota gut–brain axis. Strain A1 of B. Breve has undergone research concerning its effect on Alzheimer's. This research has consisted of mouse trials, and to date, shows promise in slowing or reversing the disease. [8]
B. breve strains were originally isolated from the feces of human infants. [9] In 1971, Bifidobacterium parvulorum and Bifidobacterium breve were merged under the name Bifidobacterium breve. [9] Bifidobacterium breve administered in combination with prebiotics, probiotics and standard therapy has showed some beneficial effect on gut health. [5] B. breve is a constituent in the therapeutic, nutritional treatment of IBD. This proprietary, standardized, formulation of live bacteria is used to treat ulcerative colitis and may require a prescription. [5] [6]
B. breve strains can ferment mannitol and sorbitol, but not arabinose or xylose. [9]
Irritable bowel syndrome (IBS) is a "disorder of gut-brain interaction" characterized by a group of symptoms that commonly include abdominal pain, abdominal bloating and changes in the consistency of bowel movements. These symptoms may occur over a long time, sometimes for years. IBS can negatively affect quality of life and may result in missed school or work or reduced productivity at work. Disorders such as anxiety, major depression, and chronic fatigue syndrome are common among people with IBS.
Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine, with Crohn's disease and ulcerative colitis (UC) being the principal types. Crohn's disease affects the small intestine and large intestine, as well as the mouth, esophagus, stomach and the anus, whereas ulcerative colitis primarily affects the colon and the rectum.
Probiotics are live microorganisms promoted with claims that they provide health benefits when consumed, generally by improving or restoring the gut microbiota. Probiotics are considered generally safe to consume, but may cause bacteria-host interactions and unwanted side effects in rare cases. There is some evidence that probiotics are beneficial for some conditions, but there is little evidence for many of the health benefits claimed for them.
Prebiotics are compounds in food that foster growth or activity of beneficial microorganisms such as bacteria and fungi. The most common environment considered is the gastrointestinal tract, where prebiotics can alter the composition of organisms in the gut microbiome.
Gut microbiota, gut microbiome, or gut flora, are the microorganisms, including bacteria, archaea, fungi, and viruses, that live in the digestive tracts of animals. The gastrointestinal metagenome is the aggregate of all the genomes of the gut microbiota. The gut is the main location of the human microbiome. The gut microbiota has broad impacts, including effects on colonization, resistance to pathogens, maintaining the intestinal epithelium, metabolizing dietary and pharmaceutical compounds, controlling immune function, and even behavior through the gut–brain axis.
Bifidobacterium animalis is a gram-positive, anaerobic, rod-shaped bacterium of the Bifidobacterium genus which can be found in the large intestines of most mammals, including humans.
Limosilactobacillus reuteri is a lactic acid bacterium found in a variety of natural environments, including the gastrointestinal tract of humans and other animals. It does not appear to be pathogenic and may have health effects.
Dysbiosis is characterized by a disruption to the microbiome resulting in an imbalance in the microbiota, changes in their functional composition and metabolic activities, or a shift in their local distribution. For example, a part of the human microbiota such as the skin flora, gut flora, or vaginal flora, can become deranged, with normally dominating species underrepresented and normally outcompeted or contained species increasing to fill the void. Dysbiosis is most commonly reported as a condition in the gastrointestinal tract.
Synbiotics refer to food ingredients or dietary supplements combining probiotics and prebiotics in a form of synergism, hence synbiotics. The synbiotic concept was first introduced as "mixtures of probiotics and prebiotics that beneficially affect the host by improving the survival and implantation of live microbial dietary supplements in the gastrointestinal tract, by selectively stimulating the growth and/or by activating the metabolism of one or a limited number of health-promoting bacteria, thus improving host welfare". As of 2018, the research on this concept is preliminary, with no high-quality evidence from clinical research that such benefits exist.
Methanobrevibacter smithii is the predominant archaeon in the microbiota of the human gut. M. smithii has a coccobacillus shape. It plays an important role in the efficient digestion of polysaccharides by consuming the end products of bacterial fermentation. Methanobrevibacter smithii is a single-celled microorganism from the Archaea domain. M. smithii is a methanogen, and a hydrogenotroph that recycles the hydrogen by combining it with carbon dioxide to methane. The removal of hydrogen by M. smithii is thought to allow an increase in the extraction of energy from nutrients by shifting bacterial fermentation to more oxidized end products.
A prokinetic agent is a type of small peptide drug which enhances gastrointestinal motility by increasing the frequency or strength of contractions, but without disrupting their rhythm. They are used to treat certain gastrointestinal symptoms, including abdominal discomfort, bloating, constipation, heart burn, nausea, and vomiting; and certain gastrointestinal disorders, including irritable bowel syndrome, gastritis, gastroparesis, and functional dyspepsia.
Bifidobacterium is a genus of gram-positive, nonmotile, often branched anaerobic bacteria. They are ubiquitous inhabitants of the gastrointestinal tract though strains have been isolated from the vagina and mouth of mammals, including humans. Bifidobacteria are one of the major genera of bacteria that make up the gastrointestinal tract microbiota in mammals. Some bifidobacteria are used as probiotics.
Xylooligosaccharides (XOS) are polymers of the sugar xylose. They are produced from the xylan fraction in plant fiber. Their C5 structure is fundamentally different from other prebiotics, which are based upon C6 sugars. Xylooligosaccharides have been commercially available since the 1980s, originally produced by Suntory in Japan. They have more recently become more widely available commercially, as technologies have advanced and production costs have fallen. Some enzymes from yeast can exclusively convert xylan into only xylooligosaccharides-DP-3 to 7.
Bacteriotherapy is the purposeful use of bacteria or their products in treating an illness. Forms of bacteriotherapy include the use of probiotics, microorganisms that provide health benefits when consumed; fecal matter transplants (FMT) /intestinal microbiota transplant (IMT), the transfer of gut microorganisms from the fecal matter of healthy donors to recipient patients to restore microbiota; or synbiotics which combine prebiotics, indigestible ingredients that promote growth of beneficial microorganisms, and probiotics. Through these methods, the gut microbiota, the community of 300-500 microorganism species that live in the digestive tract of animals aiding in digestion, energy storage, immune function and protection against pathogens, can be recolonized with favorable bacteria, which in turn has therapeutic effects.
Bifidobacterium bifidum is a bacterial species of the genus Bifidobacterium. B. bifidum is one of the most common probiotic bacteria that can be found in the body of mammals, including humans.
Microbiota-accessible carbohydrates (MACs) are carbohydrates that are resistant to digestion by a host's metabolism, and are made available for gut microbes, as prebiotics, to ferment or metabolize into beneficial compounds, such as short chain fatty acids. The term, ‘‘microbiota-accessible carbohydrate’’ contributes to a conceptual framework for investigating and discussing the amount of metabolic activity that a specific food or carbohydrate can contribute to a host's microbiota.
Psychobiotics is a term used in preliminary research to refer to live bacteria that, when ingested in appropriate amounts, might confer a mental health benefit by affecting microbiota of the host organism. Whether bacteria might play a role in the gut-brain axis is under research. A 2020 literature review suggests that the consumption of psychobiotics could be considered as a viable option to restore mental health although lacking randomized controlled trials on clear mental health outcomes in humans.
The human milk microbiota, also known as human milk probiotics (HMP), refers to the microbiota (community of microorganisms) residing in the human mammary glands and breast milk. Human breast milk has been traditionally assumed to be sterile, but more recently both microbial culture and culture-independent techniques have confirmed that human milk contains diverse communities of bacteria which are distinct from other microbial communities inhabiting the human body.
Bifidobacterium adolescentis is an anaerobic species of bacteria found in the gastrointestinal tracts of humans and other primates. It is one of the most abundant and prevalent Bifidobacterium species detected in human populations, especially in adults.
Probiotic Probio DR10, is the consumer brand name for a probiotic strain developed by Fonterra Research Development Centre (FRDC), patented and commercialised in the 1990s following the screening of over 2,000 strains. It is also known under the name of the ingredient trade mark HN019*.